Dow Jones

38 578,46

-0,28%

DAX

Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.

S'inscrire

Accueil
Investir
Actions
Etats-Unis
NASDAQ
DMK Pharmaceuticals Corporation (DMK)
DMK Pharmaceuticals Corporation (DMK) Actualités

DMK

DMK Pharmaceuticals (DMK)

DMK Pharmaceuticals Corporation

De:

Actualités Réglementées

Mots clefs:

Trier par:

Actualités Non-réglementées

Showing the most relevant articles for your search:NASDAQ:DMK

Date	Heure	Source	Titre	Symbole	Société
21/03/2024	19h23	Edgar (US Regulatory)	Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities	NASDAQ:DMK	DMK Pharmaceuticals Corporation
07/02/2024	23h19	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:DMK	DMK Pharmaceuticals Corporation
06/02/2024	16h04	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:DMK	DMK Pharmaceuticals Corporation
23/01/2024	23h23	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:DMK	DMK Pharmaceuticals Corporation
21/12/2023	14h15	GlobeNewswire Inc.	DMK Pharmaceuticals Regains Full Rights to Commercialize ZIMHI	NASDAQ:DMK	DMK Pharmaceuticals Corporation
28/11/2023	14h05	GlobeNewswire Inc.	DMK Pharmaceuticals Regains Full Rights from US WorldMeds for SYMJEPI® and Provides Corporate Update	NASDAQ:DMK	DMK Pharmaceuticals Corporation
14/11/2023	13h30	GlobeNewswire Inc.	DMK Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update	NASDAQ:DMK	DMK Pharmaceuticals Corporation
13/11/2023	16h52	GlobeNewswire Inc.	DMK Pharmaceuticals Announces Presentation of Preclinical Results Comparing Effects of DPI-125 on Opioid Withdrawal Behaviors Versus Standard of Care for Opioid Use Disorder at SfN Neuroscience 2023	NASDAQ:DMK	DMK Pharmaceuticals Corporation
02/11/2023	21h50	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:DMK	DMK Pharmaceuticals Corporation
02/11/2023	21h31	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:DMK	DMK Pharmaceuticals Corporation
30/10/2023	12h30	GlobeNewswire Inc.	DMK Pharmaceuticals Announces Inducement Option Grant Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:DMK	DMK Pharmaceuticals Corporation
19/10/2023	22h05	GlobeNewswire Inc.	DMK Pharmaceuticals Restructures Executive Team to Support Next Phase of Growth	NASDAQ:DMK	DMK Pharmaceuticals Corporation
17/10/2023	18h28	Edgar (US Regulatory)	Form PX14A6G - Notice of exempt solicitation submitted by non-management	NASDAQ:DMK	DMK Pharmaceuticals Corporation
12/10/2023	22h22	Edgar (US Regulatory)	Form DEFC14A - Definitive proxy statement, contested solicitations	NASDAQ:DMK	DMK Pharmaceuticals Corporation
02/10/2023	22h49	Edgar (US Regulatory)	Form PREC14A - Preliminary proxy statements, contested solicitations	NASDAQ:DMK	DMK Pharmaceuticals Corporation
26/09/2023	14h37	Edgar (US Regulatory)	Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]	NASDAQ:DMK	DMK Pharmaceuticals Corporation
07/09/2023	18h00	GlobeNewswire Inc.	Adamis Pharmaceuticals Changes Name to DMK Pharmaceuticals to Reflect New Strategic Focus	NASDAQ:DMK	DMK Pharmaceuticals Corporation